Renaissance Technologies - AXOVANT GENE THERAPIES LTD ownership

AXOVANT GENE THERAPIES LTD's ticker is AXGT and the CUSIP is G0750W203. A total of 1 filers reported holding AXOVANT GENE THERAPIES LTD in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of AXOVANT GENE THERAPIES LTD
ValueSharesWeighting
Q3 2020$2,037,000
+5.3%
440,923
-35.7%
0.00%0.0%
Q2 2020$1,934,000
+69.4%
685,923
+46.5%
0.00%
+100.0%
Q1 2020$1,142,000
-30.4%
468,123
+46.1%
0.00%0.0%
Q4 2019$1,641,000
-8.6%
320,423
+15.3%
0.00%
-50.0%
Q3 2019$1,796,000
-12.6%
278,023
-15.7%
0.00%0.0%
Q2 2019$2,055,000329,8230.00%
Other shareholders
AXOVANT GENE THERAPIES LTD shareholders Q4 2020
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,021,566$2,493,0001.04%
SPHERA FUNDS MANAGEMENT LTD. 2,931,018$7,152,0000.90%
Consonance Capital Management LP 3,653,303$8,914,0000.66%
Rubric Capital Management LP 460,200$1,123,0000.18%
Hudson Bay Capital Management LP 1,350,000$3,294,0000.08%
Ikarian Capital, LLC 188,884$461,0000.04%
GSA CAPITAL PARTNERS LLP 41,037$100,0000.02%
Spark Investment Management LLC 18,072$44,0000.02%
Cable Hill Partners, LLC 15,000$37,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 38,800$95,0000.01%
View complete list of AXOVANT GENE THERAPIES LTD shareholders